Daphne P Guh
Overview
Explore the profile of Daphne P Guh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
1947
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tam A, Badesha J, Guh D, Bansback N, Peter K, Hollis A, et al.
BioDrugs
. 2025 Feb;
PMID: 39998801
Background: Different biosimilar-promoting policies have been implemented worldwide to improve biosimilar uptake and reduce expenditures on costly biologics. Objective: The aim was to review biosimilar-promoting policies in 13 countries, and...
2.
Zhang W, Sun H, Guh D, Grootendorst P, Hollis A, Anis A
CMAJ
. 2024 May;
196(20):E691-E701.
PMID: 38802136
Background: The Patented Medicine Prices Review Board (PMPRB), the agency that regulates the prices of patented medicines in Canada, published proposed amendments to the regulatory framework in December 2017. Because...
3.
Zhang W, Guh D, Grootendorst P, Hollis A, Anis A
Health Policy
. 2024 Apr;
144:105064.
PMID: 38608459
Background: Canada's Patented Medicine Prices Review Board (PMPRB) uses external and internal reference pricing (IRP) to regulate patented drug list prices. PMPRB has changed external reference countries from 7 to...
4.
Mohammadi T, Guh D, Tam A, Pataky R, Black P, So A, et al.
Cancer Med
. 2023 Sep;
12(19):20106-20118.
PMID: 37740609
Background: The current prostate cancer (PCa) screening standard of care (SOC) leads to unnecessary biopsies and overtreatment because decisions are guided by prostate-specific antigen (PSA) levels, which have low specificity...
5.
Zhang W, Guh D, Mohammadi T, Pataky R, Tam A, Lynd L, et al.
Curr Oncol
. 2023 Mar;
30(3):3176-3188.
PMID: 36975453
We aimed to estimate the total health care costs attributable to prostate cancer (PCa) during care phases by age, cancer stage, tumor grade, and primary treatment in the first year...
6.
Zhang W, Sun H, Guh D, Lynd L, Hollis A, Grootendorst P, et al.
Int J Health Policy Manag
. 2020 Nov;
11(6):768-776.
PMID: 33233033
Background: Generic drug prices have been capped at specified percentages of the interchangeable branded drug's price by the Canadian provincial public drug plans since 1993. The Pan-Canadian Pharmaceutical Alliance, formed...
7.
Zhang W, Guh D, Sun H, Lynd L, Hollis A, Grootendorst P, et al.
CMAJ Open
. 2020 Sep;
8(3):E535-E544.
PMID: 32873582
Background: To monitor the magnitude of the drug shortage problem in Canada, since 2017, Health Canada has required manufacturers to report drug shortages. This study aimed to identify the factors...
8.
Nosyk B, Guh D, Bansback N, Oviedo-Joekes E, Brissette S, Marsh D, et al.
CMAJ
. 2012 Mar;
184(6):E317-28.
PMID: 22410375
Background: Although diacetylmorphine has been proven to be more effective than methadone maintenance treatment for opioid dependence, its direct costs are higher. We compared the cost-effectiveness of diacetylmorphine and methadone...
9.
Nosyk B, Guh D, Sun H, Oviedo-Joekes E, Brissette S, Marsh D, et al.
Drug Alcohol Depend
. 2011 May;
118(2-3):259-64.
PMID: 21546173
Background: While opioid substitution treatment (OST) provides the opportunity for substantial improvements in health related quality of life (HRQoL), this relationship is seldom documented and poorly understood. Our objectives were...
10.
Nosyk B, Geller J, Guh D, Oviedo-Joekes E, Brissette S, Marsh D, et al.
Drug Alcohol Depend
. 2010 Jun;
111(1-2):161-5.
PMID: 20510549
Dropout and recidivism from addiction treatment has been found to be associated with individuals' readiness for change. Motivation for treatment among participants entering the North American Opiate Medication Initiative (NAOMI)...